Predicting Life-Threatening Lung Disease from KL-6 Levels in Cancer Patients
Author Information
Author(s): Kawase Shigeo, Hattori Noboru, Ishikawa Nobuhisa, Horimasu Yasushi, Fujitaka Kazunori, Furonaka Osamu, Isobe Takeshi, Miyoshi Seigo, Hamada Hironobu, Yamane Takashi, Yokoyama Akihito, Kohno Nobuoki
Primary Institution: Hiroshima University
Hypothesis
Monitoring serum KL-6 levels can help predict the risk of life-threatening interstitial lung disease in patients treated with EGFR-TKIs.
Conclusion
The study supports the use of KL-6 as a diagnostic biomarker for life-threatening EGFR-TKIs induced interstitial lung disease.
Supporting Evidence
- 20 out of 341 patients developed EGFR-TKIs induced ILD.
- Preexisting pulmonary fibrosis was a significant risk factor for developing ILD.
- Monitoring KL-6 levels can distinguish between survivors and non-survivors.
Takeaway
Doctors can check a blood marker called KL-6 to see if lung problems might happen in cancer patients taking certain medicines.
Methodology
The study reviewed clinical records and radiographies of 341 patients with advanced NSCLCs treated with EGFR-TKIs and analyzed risk factors for ILD.
Potential Biases
The enrolled patients may not represent the general advanced NSCLC population due to selection bias.
Limitations
The study was retrospective and had a small sample size of patients with EGFR-TKIs induced ILD.
Participant Demographics
All participants were Japanese, with a mean age of 65.2 years; 49% were female.
Statistical Information
P-Value
0.003
Confidence Interval
95% CI, 1.741-12.042
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website